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ABSTRACT 
The present study was aimed at developing Gastro retentive bilayer drug delivery systems containing esomeprazole and clarithromycin for the 
treatment of H. pylori induced gastric ulcer to minimize the side effect, improve the prolongation of action, to reduce the frequency of drug 
administration. The tablet is characterized by immediate release layer of esomeprazole and Gastroretentive layer of clarithromycin. The 
formulation containing Gastroretentive layer was designed using HPMC K 15, HPMC K4 and PVP K30 as floating agents, sodium bicarbonate and 
citric acid as gas-generating agent. Crospovidone, sodium starch glycolate and croscarmellose sodium was used as superdisintegrant for the 
preparation of immediate release layer. The prepared Gastroretentive layer was evaluated for their precompression parameters, physical 
characteristics like hardness, friability, uniformity of weight, uniformity of drug content, swelling index, In-vitro floating studies and In-vitro 
drug release. The release of the esomeprazole from the immediate release layer was found to be 89.98 % in 15minutes. The release of 
clarithromycin for the sustained release floating layer was found to be 98.89±0.47% in 12 hours. The data obtained from In-vitro release were 
fitted into the various kinetic models (Zero Order, Higuchi, First Order and Korsmeyer–Peppas Model).  
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Oral route has been the most widely used and most 
convenient route for the delivery of drugs. Oral route of 
administration has received more attention than any other 
dosage form in the pharmaceutical industry and research 
field because of the flexibility in designing of dosage form 
and freedom from problems like sterility and potential 
damage at the site of administration. Approximately 50% of 
the drug delivery system in the market is oral drug delivery 
system. Drugs that are rapidly absorbed from the 
gastrointestinal tract and have a short half life are eliminated 
quickly from the blood circulation and therefore require 
frequent dosing. To avoid this problem, the oral sustain 
controlled release formulation have been developed in an 
attempt to release the drug slowly into the gastrointestinal 
tract and maintain the therapeutic drug concentration in the 
serum for longer period of time. The oral controlled-release 
system is characterized by a typical pattern of drug release in 
which the drug concentration is maintained in the 
therapeutic window for a prolonged period of time, thereby 
ensuring sustained therapeutic action1. Peptic ulcer can be 
defined as any sore in the linings of GIT particularly stomach 
or duodenum. There are two most common types of peptic 
ulcers called “gastric ulcers” and “duodenal ulcers”. Peptic 
ulcer occurs as a result of imbalance between the aggressive 
(acid, pepsin, bile and H. pylori) and the defensive (gastric 
mucus and bicarbonate secretion, prostaglandins, nitric 
oxide, innate resistance of the mucosal cells) factors. 
Helicobacter pylori are an important cause of duodenal and 
gastric ulcers. Greater than 90% of duodenal ulcers and 70% 
of gastric ulcers are associated with H. pylori. H. pylori are a 
gram-negative, motile, micro-aerophilic, curved bacillus that 
is found in the mucus layer overlying the gastric epithelium2. 
The treatment for eradication of H. pylori is complicated, 
requiring a combination of an antibiotic with gastric acid 
inhibitors. Therefore, a well designed drug delivery system is 
required to overcome the troubles of conventional therapy 
and to enhance the therapeutic efficacy of given drug 
regimens. Gastroretentive drug deliveries locate the drug 
within the stomach and prolong ultimate contact with the 
absorbing membrane and increases efficacy. This is 
particularly important in the treatment of microorganisms 
which colonize in the stomach because the three main 
fraction reducing luminal delivery of drug to them are gastric 
emptying, gastric acidity and epithelial mucus layer3. In 
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particular, H. Pylori lives deep within the gastric mucus layer 
and prolonged local application is needed for sufficient to 
diffuse to the bacteria. Esomeprazole an S-isomer of 
omeprazole that acts as proton pump inhibitor used to treat 
gastric ulcer. It suppresses acid production by inhibiting 
gastric parietal H+/K ATPase involved in hydrochloric acid 
production in the stomach4. Clarithromycin is a broad 
spectrum antimicrobial new generation macrolide active 
against most Gram positive aerobic cocci and Gram positive 
bacilli5. The activity of clarithromycin is enhanced by its 
extensive tissue distribution and by formation of the 14-(R)- 
hydroxyclarithromycin metabolite. Clarithromycin and 14-
(R)-hydroxyclarithromycin have a minimum inhibitory 
concentration of 0.03 and 0.06 μg/ml for h. pylori, 
respectively. The clarithromycin is reported that it has 
activity against h pylori bacteria that causes peptic ulcer6. 
The current investigation aims at the development of 
Gastroretentive Bilayer floating tablets with different release 
patterns of esomeprazole and clarithromycin. Clarithromycin 
is an antibiotic to treat H. Pylori and esomeprazole is proton 
pump inhibitor to reduce gastric acid secretion. 
MATERIALS AND METHODS 
Esomeprazole and Clarithromycin were gifted by Aurobindo 
Pharma Limited, Hyderabad A.P, India. HPMC K4M, K15M, 
PVP K30 was obtained from Mapromax, Life sciences Pvt. 
Ltd. Dehradun. Sodium bicarbonate, citric acid, magnesium 
stearate and talc were obtained from Loba Chemical Pvt Ltd 
(Mumbai, India). Crospovidone, Sodium starch glycolate, 
Croscarmellose sodium obtained from Danmed 
Pharmaceuticals Pvt Ltd, Hyderabad. Hydrochloric acid was 
obtained from S. D. Fine Chem. Ltd., Mumbai. All other 
chemical were purchased from Hi Media, Mumbai. Double 
distilled water was prepared freshly and used whenever 
required. All other chemicals used in this study including 
those stated were of analytical reagent (A.R.) grade. 
Formulation Development  
Formulation of immediate release (IR) layer 
Fast dissolving tablets of Esomeprazole were prepared by 
direct compression method after incorporating different 
superdisintegrants such as, crosscarmellose sodium (Ac-Di-
Sol), crospovidone and sodium starch glycolate in different 
concentrations. All the ingredients given in table 1 were 
weighed and mixed in geometric progression in a dry and 
clean mortar. Then the ingredients were passed through 
mesh #60. The Blend was compressed on 8 mm (diameter) 
fat punches on a ‘Rimek mini press 16 station rotary 
compression machine. Nine formulations of Esomeprazole  
granules were prepared and  each  formulation  contained  
one  of  the  three  disintegrate  in  different concentration. 
Each tablets weighing 100 mg, were obtained. Composition 
of tablets is mentioned in Table 1. 
 
Table 1 Composition of esomeprazole fast dissolving tablets 
Ingredients(mg) 
Formulation code 
IF1 IF2 IF3 IF4 IF5 IF6 IF7 IF8 IF9 
Esomeprazole  40 40 40 40 40 40 40 40 40 
Sodium Starch glycolate 10 15 20 - - - - - -_ 
Croscarmellose sodium - - - 10 15 20 -_ -_ -_ 
Crospovidone -_ _- - _- -_ _- 10 15 20 
Microcrystalline cellulose 39 34 29 39 34 29 39 34 29 
Talc 5 5 5 5 5 5 5 5 5 
Magnesium stearate 6 6 6 6 6 6 6 6 6 
Total weight 100 100 100 100 100 100 100 100 100 
 
 
Formulation of floating sustained release (SR) layer 
Direct compression was followed to manufacture the gas 
generating floating tablets of Clarithromycin. Nine different 
formulations (F1, F2, F3, F4, F5, F6, F7, F8, & F9) were 
prepared by direct compression. All the polymers selected, 
drug and excipients were passed through sieve no. 40 before 
using into formulation. The amount and ratio of drug and 
polymers were weighed as per given in table 2 and all the 
formulation were used for further evaluations parameters. 
 
Table 2 Various formulations of clarithromycin gastro retentive tablet  
 
Excipients(mg) F1    F2     F3    F4   F5 F6    F7    F8    F9 
Clarithromycin  250 250 250 250 250 250 250 250 250 
HPMC K 15 _ _ _ 120 140 160 60 70 80 
HPMC K 4 120 140 160 _ _ _ 60 70 80 
PVP K30 15 15 15 15 15 15 15 15 15 
Citric acid 5 5 5 5 5 5 5 5 5 
NaHCO3 15 15 15 15 15 15 15 15 15 
Mg(C18H35O2)2 5 5 5 5 5 5 5 5 5 
Talc 5 5 5 5 5 5 5 5 5 
Lactose 85 65 45 85 65 45 85 65 45 
Total Weight 500 500 500 500 500 500 500 500 500 
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Formulation of bilayer tablet 
Optimized formulation IF-6 of Instant release layer 
(Esomeprazole) and optimized formulation of F-5 
(clarithromycin) for control release used for formulation of 
Bi-layer tablet. 
Evaluation of Precompression Parameter  
Angle of repose (θ) 
The angle of repose was determined by using fixed funnel 
method. The physical mixtures of drug with different 
excipients were prepared and the accurately weighed drug 
powder or its physical mixture was taken in a funnel. The 
height of the funnel was adjusted in such a way that the tip of 
the funnel just touches the apex of the heap of the drug 
powder. The powder was allowed to flow through the funnel 
freely onto surface. The angle of repose was calculated using 
the following equation. 
θ = tan-1(h/r) 
Where, h and r are the height and radius of the powder cone 
respectively. 
Bulk density/tapped density 
Both loose bulk density (LBD) and tapped density (TBD) 
were determined were calculated using the following 
formulas. 
LBD = Powder weight/volume of the packing 
TBD = Powder weight /tapped volume of the packing 
Compressibility index 
 The compressibility index of the granules was determined 
by Carr’s compressibility index. 
Carr’s index (%) = [(TBD – LBD)/TBD] × 100. 
Hausner’s ratio 
Hausner’s ratio is an indirect index of ease of measuring the 
powder flow. It was calculated by the following formula7-9. 
Hausner’s ratio = Tapped density/Bulk density. 
Evaluation of Post Compression Parameter  
Shape and color of tablets 
Uncoated tablets were examined under a lens for the shape 
of the tablet and colour was observed by keeping the tablets 
in light. 
Thickness 
Three tablets were picked from each formulation randomly 
and thickness was measured individually. It is expressed in 
mm and standard deviation was also calculated. The tablet 
thickness was measured using dial-caliper (Mitutoyo, Japan). 
Hardness 
For each formulation, the hardness of five tablets was 
determined using the Monsanto hardness tester (Cadmach) 
and measured in terms of kg/cm2. 
Weight variation 
Twenty tablets were selected randomly from each 
formulation and average weight was determined.  The 
tablets were weighed individually and compared with 
average weight. The U.S Pharmacopoeia allows a little 
variation in the weight of a tablet. 
 
Friability 
A sample of twenty randomly selected tablets were 
accurately weighed and placed in a Roche friabilator. The 
friabilator was operated for 4 min at a speed of 25 rpm. The 
tablets were removed from the friabilator, de-dusted and 
reweighed. The percent loss in weight due to abrasion and 
impact was calculated as, 
%Friability= (Loss in weight/ Initial weight) x 100 
Hardness test 
The hardness of tablet was measured by Pfizer hardness 
tester and results were expressed in Kg/cm2. 
Uniformity of drug content for IR tablet  
The test is mandatory for tablets with 10 mg or less weight 
of active ingredient. Ten randomly selected tablets from each 
formulation (F1 to F9) were finely powdered and Drug 
equivalent  to  10  mg of drug dissolved in 10 ml  0.1  N  HCl  
(simulated gastric ﬂuid  of pH 1.2 without enzymes) sonicate 
it for 20 minutes,  till  the  entire  drug leached  out  from  
complex,  then  the  solution was  filtered  through  whatman  
filter  paper No. 41. From this Solution take 1 ml and Diluted 
up to 100 ml with 0.1 N HCl and the drug content was 
determined spectrophotometrically at 282.0nm for 
Esomeprazole. 
Drug content for SR tab 
Twenty tablets were taken and amount of drug present in 
each tablet was determined. The tablets were crushed in a 
mortar and the powder equivalent to 100mg of drug was 
transferred to 100ml standard flask. The powder was 
dissolved in 50 ml of 0.1 N Hcl and made up to volume with 
of 0.1 N HCl. The sample was mixed thoroughly and filtered 
through a 0.45μ membrane filter. The filtered solution was 
diluted suitably and react with dye and analyzed for drug 
content by UV spectrophotometer at a λ max of 414.0 nm 
using of 0.1 N HCL as blank. 
Drug content 
Twenty tablets were taken and amount of drug present in 
each tablet was determined. The tablets were crushed in a 
mortar and the powder equivalent to 25 mg of 
clarithromycin was transferred to 100ml standard flask. The 
powder was dissolved in 25 ml of 0.1 N HCL and made up to 
volume with 0.1 N HCL. The sample was mixed thoroughly 
and filtered through a 0.45μ membrane filter. The filtered 
solution was further diluted 0.1 ml to 10 ml suitably (10 ppm 
of clarithromycin) and prepares individually 10 ppm 
solution of Esomeprazole  determine the Conc. of both drugs 
using 282 nm and 416nm for Esomeprazole  and 
clarithromycin respectively. 
In vitro buoyancy studies 
In vitro buoyancy was determined by floating lag time as per 
the method described by Rosa et al. The tablets were placed 
separately in a 100 ml glass beaker containing simulated 
gastric fluid (SGF), pH 1.2 as per USP. The time required for 
the tablet to rise to the surface and float was determined as 
floating lag time 
Dissolution rate studies of SR tab 
In vitro drug release of the sample was carried out using 
USP- type II dissolution apparatus (Paddle type). The 
dissolution medium, 900 ml 0.1N HCl was placed into the 
dissolution flask maintaining the temperature of 37±0.50c 
and rpm of 75. One Clarithromycin tablet was placed in each 
basket of dissolution apparatus. The apparatus was allowed 
to run for 10 hours. Sample measuring 5 ml were withdrawn 
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after every 1 hour up to 10 hours using 10ml pipette. The 
fresh dissolution medium (370C) was replaced every time 
with the same quantity of the sample. From this take 0.5 ml 
and dilute up to 10 ml with 0.1 N HCL, react with dye (methyl 
orange) and extract with chloroform and take the 
absorbance at 416.0 nm using spectroscopy. 
Dissolution rate studies of Bilayer tab 
In vitro drug release was performed according to the USP 
dissolution apparatus II at 50 rpm and 37±0.5ºC 
temperature over a 12 hrs periods for clarithromycin SR and 
1 hr for Esomeprazole IR, using an automated paddle 
dissolution system (Labindia). A minimum of 6 tablets per 
batch were tested. The media used was 0.1N HCl at a pH 1.2 
and a volume of 900 ml was maintained at 37±0.5◦C. Test 
sample (1ml) was withdrawn at particular time interval and 
replaced with fresh dissolution media maintained at the 
same temperature and the concentration of dissolved drug 
was determined using U.V. (Ultraviolet Labindia 3000+) 
spectrophotometer at λmax 282nm for Esomeprazole and 
416 nm for clarithromycin respectively. 
RESULTS AND DISCUSSIONS 
λ max of Esomeprazole and Clarithromycin was found to be 
282 and 416 nm by using U.V. spectrophotometer (Labindia-
3000+) Fig.1& 2. 
 
 
Figure 1 Determination of λmax of Clarithromycin 
 
 
Figure 2 Determination of λmax of Esomeprazole 
 
The powdered blends of different formulations of sustained 
release floating tablets were evaluated for angle of repose, 
bulk density (BD), tapped density (TBD) and compressibility 
index. The results of SR floating tablets are summarized in 
Table 3. The results of SR floating tablets of BD and TBD 
ranged from 0.570±0.007 to 0.585±0.003 and 0.728±0.005 to 
0.792±0.005 respectively. The range of Hausner ratio and 
compressibility index was found to be 0.720±0.03 to 
0.739±0.03 and 27.30±0.68 to 36.24±0.70 respectively. The 
results of angle of repose (<35) indicate good flow properties 
of the powdered blend. The formulation of immediate 
release tablet prepared by using the superdisintegrants 
exhibited the LBD, TBD, angle of repose, compressibility 
index and Hausner’s ratio of within the range, which shows 
good flow properties of the powdered blend. The prepared 
tablets were evaluated for different physico-chemical 
properties and the results are summarized in Table 4 & 5. 
The tablets were white, circular in shape and were found to 
be uniform with respect to weight variation, hardness; 
thickness, friability and content uniformity of different batch 
of tablets were found within acceptable range and the 
distribution of drug in all the formulations was uniform. The 
in-vitro drug release of GRF tablets was found in range of 
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F1 0.582±0.002 0.732±0.007 27.33±0.73 0.721±0.01 
F2 0.581±0.008 0.730±0.006 28.33±0.72 0.723±0.01 
F3 0.576±0.002 0.728±0.005 27.30±0.68 0.720±0.01 
F4 0.570±0.007 0.729±0.003 29.30±0.65 0.726±0.03 
F5 0.580±0.003 0.735±0.004 30.30±0.61 0.730±0.04 
F6 0.585±0.003 0.732±0.006 32.80±0.64 0.728±0.06 
F7 0.582±0.004 0.742±0.003 36.24±0.70 0.720±0.03 
F8 0.579±0.002 0.792±0.005 29.72±0.68 0.720±0.04 
F9 0.584±0.004 0.768±0.004 28.52±0.71 0.739±0.03 
 




















Time (sec.) (n=3) 
Mean ± SD 
IF1 3.5 0.485 Passes 2.1 98.56 180±5 
IF2 3.6 0.852 Passes 2.2 97.45 120±6 
IF3 3.5 0.765 Passes 2.3 98.25 100±8 
IF4 3.5 0.898 Passes 2.1 98.12 170±7 
IF5 3.3 0.745 Passes 2.1 97.75 100±8 
IF6 3.2 0.658 Passes 2.2 98.65 90±4 
IF7 3.3 0.458 Passes 2.2 97.45 130±5 
IF8 3.4 0.658 Passes 2.3 97.45 140±6 
IF9 3.4 0.741 Passes 2.4 98.12 150±7 
 
Table 5 Results of Post Compression Properties of Clarithromycin FGR Tablets 

















F1 3.53±0.05 4.8 500.19± 2.94 0.58 ± 0.10 98.33± 0.92 8 28 Sec. 
F2 3.94± 0.10 4.4 500.18 ± 3.77 0.51 ± 0.08 97.20 ± 0.34 10 25 Sec. 
F3 3.96± 0.05 4.5 500.33 ± 1.50 0.38 ± 0.12 99.60 ± 1.39 >12 33 Sec. 
F4 3.95± 0.05 4.7 500.30 ± 3.30 0.16 ± 0.04 98.14 ± 1.69 >12 35 Sec. 
F5 3.93± 0.10 5.2 500.13 ± 2.83 0.31 ± 0.07 97.21 ± 1.07 >12 36 Sec. 
F6 4.03± 0.06 5.3 500.16 ± 2.33 0.27 ± 0.05 97.50± 1.81 >12 35 Sec. 
F7 4.05± 0.05 4.8 500.18 ± 3.11 0.29 ± 0.08 98.34 ± 0.37 >12 31 Sec. 
F8 3.98± 0.05 4.5 500.04 ± 2.56 0.34 ± 0.12 98.31± 0.91 >12 30 Sec. 
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Table 6  In-vitro Drug Release Study of GRF Tablets 
Time % Cumulative Drug Release 
(hr) F1 F2 F3 F4 F5 F6 F7 F8 F9 
0.5 35.65 33.56 30.45 28.89 25.65 22.19    20.15 18.98 12.25 
1 45.65 40.12 38.89 35.65 31.45 30.12    25.65 22.32 18.98 
1.5 55.69 50.65 48.98 43.14 42.12 38.23    32.13 26.28 25.65 
2 69.98 65.56 52.12 49.98 48.23 46.32    47.14 38.21 40.28 
3 98.78 89.98 69.98 63.45 61.12 55.56    55.65 45.65 46.65 
4 - 99.45 85.65 80.12 75.65 62.12    65.45 55.65 54.45 
6 - - 98.78 91.45 83.12 69.45    73.23 64.45 60.12 
8 - - - 98.78 88.65 77.89    80.23 70.23 69.12 
12 - - - - 98.89 83.23    85.65 78.98 75.63 
 
The prepared bilayer tablets were evaluated for different 
physico-chemical properties and the results are summarized 
in Table 7. The tablets were found to be uniform with respect 
to weight variation and hardness (5.45 ± 0.21kg/cm2). The 
thickness (5.4 ±0.2mm) and friability (0.725± 0.01%) of 
optimized batch of tablets were found within acceptable 
range. Content uniformity of formulations was found to be 
99.46 %, where the distribution of drug in all the 
formulations was uniform. The Instant layer of 
Esomeprazole release Approx 89.98 percent drug within 15 
minutes and control floating layer Clarithromycin shows 
release up to 12 Hours Approx 98.89±0.47 percent. The 
release of bilayer tablet is shown in Fig.2.  
 













1. 5.45 ± 0.21 0.725± 0.01 Passes 5.4 ±0.2 99.46±0.21 
 
 
Figure 3 Graph of Release of Bilayer tablets 
CONCLUSION 
The Experiment relates to formulation and development of 
oral pharmaceutical bilayer tablet of esomeprazole and 
clarithromycin for administration of therapeutically and 
prophylactically effective amount of drug substance to obtain 
both a relatively fast or quick onset of therapeutic effect and 
mainatainence of a therapeutically active plasma 
concentration for relatively long period of time. Experiment 
conclude that Bi-layer tablet is suitable for delivering drugs 
with different release pattern like one layer of drug as 
immediate release to get quick relief and second drug as 
sustained release of drug which gives effect of drug for 
sufficient long time and reduce frequency of dose. 
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